药物暴露与最低抑菌浓度预测肺结核治疗反应
该研究对培养确诊结核病患者进行药代动力学采样和MIC测定,用CART分析获得一线药物预测2周/月培养转阴、6-8个月治疗结局、急性肾损伤和药物性肝损伤的PK/PD阈值,并用LASSO logistic回归建模验证。最终168例和52例分别纳入开发与验证队列,AUC/MIC低于CART阈值等指标与临床结局和不良反应相关。
要点
- 吡嗪酰胺AUC/MIC低于8.42预测2周培养转阴。
- 吡嗪酰胺AUC/MIC低于2.79预测2个月培养转阴。
- 利福平AUC/MIC低于435.45预测治疗成功。
核心结论
- 结核药物PK/PD指数和药物暴露与临床结局及不良反应相关。
- CART所得阈值用于个体化给药对治疗结局的影响需随机对照试验研究。
研究设计与样本
- 对培养确诊结核病患者进行药代动力学采样和MIC测定,用CART分析获得PK/PD阈值,用LASSO logistic回归建模验证。
- 开发队列168例,验证队列52例。
主要发现
- 吡嗪酰胺AUC/MIC低于8.42、吡嗪酰胺AUC/MIC低于2.79或利福平AUC/MIC低于435.45分别是2周培养转阴、2个月培养转阴或治疗成功的主要预测因素。
- 异烟肼AUC>21.78 mg·h/L或利福平AUC>82.01 mg·h/L可预测治疗期间药物性肝损伤或急性肾损伤。
- 训练LASSO模型在验证队列的ROC曲线下面积为0.625至0.978。
关键数值与推荐
- 吡嗪酰胺AUC/MIC阈值8.42预测2周培养转阴。
- 吡嗪酰胺AUC/MIC阈值2.79预测2个月培养转阴。
- 利福平AUC/MIC阈值435.45预测治疗成功。
- 异烟肼AUC>21.78 mg·h/L预测药物性肝损伤。
- 利福平AUC>82.01 mg·h/L预测急性肾损伤。
临床怎么用
- 可参考CART推导的PK/PD阈值评估结核治疗反应和不良反应风险。
- 个体化给药需随机对照试验验证对治疗结局的影响。
局限性
- 原文未报告具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Prospective studies correlating pharmacokinetic/pharmacodynamic (PK/PD) indices to clinical responses are urgently needed. This study aimed to find clinically relevant PK/PD thresholds that can be used for treatment optimization. METHODS: Pharmacokinetic sampling and minimum inhibitory concentration (MIC) measurements were performed for patients with culture-confirmed tuberculosis (TB). Classification and regression tree (CART) analysis was applied to obtain PK and/or PD thresholds for first-line drugs predictive of 2-week/month culture conversion, treatment outcome determined at 6-8 months, acute kidney injury (AKI), and drug-induced liver injury (DILI). Least absolute shrinkage and selection operator (LASSO) logistic regression was used for model development and validation. RESULTS: Finally, 168 and 52 patients with TB were included in development and validation cohorts for analysis, respectively. Area under the concentration-time curve (AUC)/MIC below CART-derived thresholds for pyrazinamide of 8.42, pyrazinamide of 2.79, or rifampicin of 435.45 were the predominant predictors of 2-week culture conversion, 2-month culture conversion, or treatment success, respectively. Isoniazid AUC >21.78 mg · h/L or rifampicin AUC >82.01 mg · h/L were predictive of DILI or AKI during TB treatment. The predictive performance of trained LASSO models in the validation cohort was evaluated by receiver operating characteristic curves and ranged from 0.625 to 0.978. CONCLUSIONS: PK/PD indices and drug exposure of TB drugs were associated with clinical outcome and adverse events. The effect of CART-derived thresholds for individualized dosing on treatment outcome should be studied in a randomized controlled trial.
引用
- Zheng X, Bao Z, Forsman LD, et al. Drug Exposure and Minimum Inhibitory Concentration Predict Pulmonary Tuberculosis Treatment Response. Clin Infect Dis. 2021. PMID: 33070176. doi:10.1093/cid/ciaa1569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。